To ensure the integrity of all content produced by the Lymphoma Coalition (LC), a rigorous process has been put in place that entails the gathering and validation of information that is shared with the general public, its members, social media and the website. All content is validated prior to publication as described under Editorial Procedure below.
LC has enlisted an Editorial Guidelines Committee made up of members of the LC Medical Advisory Board, LC members, LC CEO, pharmaceutical representatives and healthcare professionals. The committee offers feedback and guidance on publications, topics, and process and procedures.
LC reviews up to 500 RSS feeds each week that focus on findings from clinical trials and medical research from peer-reviewed journals (e.g., Journal of Clinical Oncology, Blood) regulatory agencies (e.g., Food and Drug Administration, the National Comprehensive Cancer Network, European Society of Medical Oncology), conference proceedings (e.g., American Society of Hematology annual meeting, the American Society of Clinical Oncology annual meeting, European Hematology Association Congress, the International Conference on Malignant Lymphomas etc), clinical trial registries and general news media. The information is then divided between content development, the member Resource Library, newsletters and the website.
LC receives information from other sources, e.g., news releases issued by pharmaceutical companies, publications on single institution retrospective studies and while LC archives this information, LC does not use it as a single source of information.
All content for LC is developed by a healthcare writer under the guidance of the Chief Executive Officer (CEO).
Content development entails reviewing research gathered by LC’s research coordinator as well as interviewing healthcare professionals, representatives from relevant healthcare organisations and LC members.
Any clinical or medical content developed by LC based solely on its own research is first reviewed by the CEO and then reviewed and approved by a member of LC’s medical advisory board or a specialist medical professional involved in the development of the article prior to publication.
All other content developed is first reviewed by the Director of Strategic Communication and Engagement, the CEO and then reviewed and approved by the respective organisation or parties involved prior to publication.
All articles are dated with the publication date and the author(s) is sited.